ER-Positive Luminal B Breast Cancers and Body Mass Index Inversely Associated With HER2 Expression

ER-Positive Luminal B Breast Cancers and Body Mass Index Inversely Associated With HER2 Expression
A recent study on genomic and transcriptomic profiling of luminal B breast cancer entitled “Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal b breast cancer” was published in the Journal of Cellular Physiology by Dr. Maddalena Barba and colleagues, Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy. Breast cancer is the most common type of cancer affecting women in the world. It can be divided into four important subtypes based on biological markers: luminal A, luminal B, Triple negative/basal-like and HER2 over-expressing breast cancer. The Luminal A and B subtypes are both estrogen-receptor-positive (ER+) and low-grade, with Luminal B tumors associated with an overall worst prognosis. “Breast cancer is a complex disease. Such complexity is faithfully mirrored by its clinical phenomenology and etiopathogenesis, namely, the way several risk factors may combine according to mechanisms characterized by flexibility and heterogeneity with alternative and innovative patterns changing from patient to patient” said Dr. Maddalena Barba, in a 
Subscribe or to access all post and page content.